Results 101 to 110 of about 577,451 (225)
Indian Journal of Radiology and Imaging, 2006 Cerebral amyloid angiopathy (CAA) is a very rare entity. This is an age related disease and is not a manifestation of systemic amyloidosis in any of its forms. Sporadic cases are most common, though hereditary cases do exist. Alzheimer's disease predispose to CAA.
BKD Prasad, GS Kejriwal, SN Sahu
openaire +1 more source
A murine model of amyloid enhanced tauopathy: progressive changes in tau pathology and behavior
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract BACKGROUND Our prior work demonstrated systemic P301L‐tau injections in mice with mature amyloid resulted in several‐fold enhancement of tauopathy compared to non‐transgenic (NTg) littermates. METHODS APP+PS1 mice were injected intravenously with AAV.CAP‐B10 expressing P301L tau (A/P+P301L).
Dylan J. Finneran +4 more
wiley +1 more source
Stroke caused by cerebral amyloid angiopathy: a case of difficult diagnosis [PDF]
Dementia & Neuropsychologia. Cerebral amyloid angiopathy is a common cause of intracerebral hemorrhage, most often occurring in older adults and in patients with dementia. One of its main differential diagnoses is hypertensive intracerebral hemorrhage.
Rocío Campos Gamarra +2 more
doaj +1 more source
Reply to “CSF Amyloid‐β Risk Stratification in CAA: A Missing Link for Anti‐Amyloid Therapy Safety”
Annals of Neurology, Volume 100, Issue 5, Page 1118-1119, November 2026.
Philipp Arndt, Stefanie Schreiber
wiley +1 more source
Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti‐amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co‑pathology on the treatment effects remains incomplete.
Lieza G Exalto +6 more
wiley +1 more source
Alzheimer’s Research & TherapyMonoclonal antibodies targeting amyloid-β are the first approved disease-modifying treatment for Alzheimer’s disease. While amyloid-targeting therapies mitigate the progression of cognitive decline in early-stage Alzheimer’s disease, they are associated ...
Jonathan Merkel +8 more
doaj +1 more source
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract BACKGROUND Tau pathology in Alzheimer's disease (AD) propagates along the brain's connectome, yet the mechanisms by which tau drives neuronal dysfunction remain unclear. We hypothesized that dysfunction primarily emerges in regions close to tau‐harboring epicenters. METHODS One hundred thirty‐one amyloid‐positive individuals underwent dynamic [
Lukas Frontzkowski +28 more
wiley +1 more source
Vascular drivers of cerebrospinal fluid movement and enlarged perivascular spaces
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract Perivascular spaces (PVSs) facilitate cerebrospinal fluid flow and waste clearance, which are critical for maintaining brain homeostasis. Enlarged PVSs (ePVSs) are an emerging marker of cerebral small vessel disease and are implicated in protein accumulation, neurodegeneration, and cognitive decline.
James D. LeFevre +2 more
wiley +1 more source
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract BACKGROUND Individuals with Alzheimer's disease (AD) dementia can be subgrouped based on cognitive performance at diagnosis. We compared neuropathology across cognitively defined AD subgroups in the Adult Changes in Thought study. METHODS Scores for memory, executive functioning, language, and visuospatial abilities were derived from the ...
Caitlin S. Latimer +12 more
wiley +1 more source
Retinal Vascular Abnormalities in Patients with Cerebral Amyloid Angiopathy
, 2009 Cerebral amyloid angiopathy (CAA) accounts for 10% of all intracerebral hemorrhage.
Celia Chen; Mark Agzarian; Sandy Patel; Andrew Lee
core